BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21928314)

  • 1. Impact of residual normal metaphases in core binding factor acute myeloid leukemia.
    Medeiros BC; Othus M; Fang M; Appelbaum FR; Estey EH
    Cancer; 2012 May; 118(9):2420-3. PubMed ID: 21928314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of residual normal metaphases in acute myeloid leukemia with t(8;21)(q22;q22).
    Wen L; Xia J; Wang Q; Yao H; Xie J; Pan J; Xue Y; Wu D; Chen S
    Int J Hematol; 2015 Aug; 102(2):205-10. PubMed ID: 26040504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
    Mosna F; Papayannidis C; Martinelli G; Di Bona E; Bonalumi A; Tecchio C; Candoni A; Capelli D; Piccin A; Forghieri F; Bigazzi C; Visani G; Zambello R; Zanatta L; Volpato F; Paolini S; Testoni N; Gherlinzoni F; Gottardi M
    Am J Hematol; 2015 Jun; 90(6):515-23. PubMed ID: 25753065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype.
    Marcault C; Boissel N; Haferlach C; Loschi M; Raynaud S; Cluzeau T
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e199-e205. PubMed ID: 34674982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.
    Breems DA; Van Putten WL; De Greef GE; Van Zelderen-Bhola SL; Gerssen-Schoorl KB; Mellink CH; Nieuwint A; Jotterand M; Hagemeijer A; Beverloo HB; Löwenberg B
    J Clin Oncol; 2008 Oct; 26(29):4791-7. PubMed ID: 18695255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A multivariate model for predicting induction response and prognosis in core binding factor acute myeloid leukemia].
    Wang B; Hua XY; Lin RR; Yang B; Wu W; He B; Zhang XW; Xing SS; Li HQ
    Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):796-802. PubMed ID: 31665853
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical and cytogenetic features and their influencing factors of core binding factor acute myeloid leukemia].
    Li W; Mi YC; Liu BC; Zhou CL; Lin D; Wang HJ; Liu XP; Li QH; Bian SG; Wang JX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Oct; 33(5):517-24. PubMed ID: 22338135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
    Hemmati PG; Schulze-Luckow A; Terwey TH; le Coutre P; Vuong LG; Dörken B; Arnold R
    Eur J Haematol; 2014 Feb; 92(2):102-10. PubMed ID: 24138573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.
    Strickland SA; Sun Z; Ketterling RP; Cherry AM; Cripe LD; Dewald G; Fernandez HF; Hicks GA; Higgins RR; Lazarus HM; Litzow MR; Luger SM; Paietta EM; Rowe JM; Vance GH; Wiernik P; Wiktor AE; Zhang Y; Tallman MS;
    Leuk Res; 2017 Aug; 59():55-64. PubMed ID: 28551161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
    Chen W; Xie H; Wang H; Chen L; Sun Y; Chen Z; Li Q
    PLoS One; 2016; 11(1):e0146614. PubMed ID: 26771376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients.
    Mori A; Onozawa M; Hidaka D; Yokoyama S; Miyajima T; Yokoyama E; Ogasawara R; Izumiyama K; Saito M; Fujisawa S; Ota S; Kakinoki Y; Tsutsumi Y; Yamamoto S; Miyagishima T; Nagashima T; Iwasaki H; Kobayashi H; Haseyama Y; Kurosawa M; Morioka M; Teshima T; Kondo T
    Int J Hematol; 2022 Feb; 115(2):188-197. PubMed ID: 34739701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
    Shin HJ; Min WS; Min YH; Cheong JW; Lee JH; Kim IH; Hong DS; Ahn JS; Kim HJ; Lee WS; Jung CW; Jang JH; Park Y; Kim HJ;
    Ann Hematol; 2019 May; 98(5):1135-1147. PubMed ID: 30758645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.
    Sperr WR; Zach O; Pöll I; Herndlhofer S; Knoebl P; Weltermann A; Streubel B; Jaeger U; Kundi M; Valent P
    Am J Hematol; 2016 Dec; 91(12):1239-1245. PubMed ID: 27643573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of residual normal metaphases in acute myelogenous leukemia patients presenting with abnormal karyotype.
    Ghaddar HM; Pierce S; Reed P; Estey EH
    Leukemia; 1995 May; 9(5):779-82. PubMed ID: 7769840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytogentic and prognostic characteristic of acute myeloid leukemia with monosomal karyotype].
    Li Z; Wei H; Lin D; Zhou CL; Liu BC; Wang Y; Liu KQ; Li W; Gong BF; Wei SN; Zhang GJ; Zhao XL; Li Y; Liu YT; Gong XY; Gu RX; Qiu SW; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):366-71. PubMed ID: 27210869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
    Huh J; Kim HJ; Jung CW; Kim HJ; Kim SH; Kim YK; Kim HJ; Shin MG; Moon JH; Sohn SK; Kim SH; Lee WS; Won JH; Mun YC; Kim H; Park J; Min WS; Kim DH;
    Am J Hematol; 2012 Oct; 87(10):961-8. PubMed ID: 22886749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype.
    Baron F; Stevens-Kroef M; Kicinski M; Meloni G; Muus P; Marie JP; Halkes CJM; Thomas X; Vrhovac R; Albano F; Lefrère F; Sica S; Mancini M; Venditti A; Hagemeijer A; Jansen JH; Amadori S; de Witte T; Willemze R; Suciu S
    Haematologica; 2019 Jun; 104(6):1168-1175. PubMed ID: 30523055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
    Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
    Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.